Efficacy and safety of the oral direct factor Xa inhibitor apixaban for symptomatic deep vein thrombosis. The Botticelli DVT dose‐ranging study
Botticelli investigators, the writing … - … of Thrombosis and …, 2008 - Wiley Online Library
Background: Apixaban, an oral potent reversible direct inhibitor of activated factor X, has
shown promise in the prevention of venous thromboembolism following major orthopedic …
shown promise in the prevention of venous thromboembolism following major orthopedic …
[引用][C] Efficacy and safety of the oral direct factor Xa inhibitor apixaban for symptomatic deep vein thrombosis. The Botticelli DVT dose‐ranging study
H BULLER, D DEITCHMAN, M PRINS… - Journal of Thrombosis …, 2008 - cir.nii.ac.jp
Efficacy and safety of the oral direct factor Xa inhibitor apixaban for symptomatic deep vein
thrombosis. The Botticelli DVT dose‐ranging study | CiNii Research CiNii 国立情報学研究所 …
thrombosis. The Botticelli DVT dose‐ranging study | CiNii Research CiNii 国立情報学研究所 …
Efficacy and safety of the oral direct factor Xa inhibitor apixaban for symptomatic deep vein thrombosis. The Botticelli DVT dose-ranging study.
N Renseigné, H Buller, D Deitchman… - … of Thrombosis and …, 2008 - ujm.hal.science
BACKGROUND: Apixaban, an oral potent reversible direct inhibitor of activated factor X, has
shown promise in the prevention of venous thromboembolism following major orthopedic …
shown promise in the prevention of venous thromboembolism following major orthopedic …
Efficacy and safety of the oral direct factorXa inhibitor apixaban for symptomatic deep vein thrombosis. The Botticelli DVT dose-ranging study
H Buller, D Deitchman, M Prins… - Journal of …, 2008 - researchportal.murdoch.edu.au
BACKGROUND: Apixaban, an oral potent reversible direct inhibitor of activated factor X, has
shown promise in the prevention of venous thromboembolism following major orthopedic …
shown promise in the prevention of venous thromboembolism following major orthopedic …
[HTML][HTML] Efficacy and safety of the oral direct factor Xa inhibitor apixaban for symptomatic deep vein thrombosis. The Botticelli DVT dose‐ranging study
H BULLER, D DEITCHMAN, M PRINS… - Journal of Thrombosis …, 2008 - jthjournal.org
Background: Apixaban, an oral potent reversible direct inhibitor of activated factor X, has
shown promise in the prevention of venous thromboembolism following major orthopedic …
shown promise in the prevention of venous thromboembolism following major orthopedic …
Efficacy and safety of the oral direct factor Xa inhibitor apixaban for symptomatic deep vein thrombosis. The Botticelli DVT dose-ranging study.
H Buller, D Deitchman, M Prins… - Journal of Thrombosis …, 2008 - europepmc.org
Background Apixaban, an oral potent reversible direct inhibitor of activated factor X, has
shown promise in the prevention of venous thromboembolism following major orthopedic …
shown promise in the prevention of venous thromboembolism following major orthopedic …
[HTML][HTML] Efficacy and safety of the oral direct factor Xa inhibitor apixaban for symptomatic deep vein thrombosis. The Botticelli DVT dose‐ranging study
THEW COMMITTEE, H BULLER… - Journal of Thrombosis …, 2008 - Elsevier
Background: Apixaban, an oral potent reversible direct inhibitor of activated factor X, has
shown promise in the prevention of venous thromboembolism following major orthopedic …
shown promise in the prevention of venous thromboembolism following major orthopedic …
Efficacy and safety of the oral direct factor Xa inhibitor apixaban for symptomatic deep vein thrombosis. The Botticelli DVT dose-ranging study.
N Renseigné, H Buller, D Deitchman, M Prins… - Journal of Thrombosis …, 2008 - hal.science
BACKGROUND: Apixaban, an oral potent reversible direct inhibitor of activated factor X, has
shown promise in the prevention of venous thromboembolism following major orthopedic …
shown promise in the prevention of venous thromboembolism following major orthopedic …
[引用][C] Efficacy and safety of the oral direct factor Xa inhibitor apixaban for symptomatic deep vein thrombosis. The Botticelli DVT dose-ranging study.
I Botticelli, H Buller, D Deitchman, M Prins… - JOURNAL OF …, 2008 - research.unipg.it
Efficacy and safety of the oral direct factor Xa inhibitor apixaban for symptomatic deep vein
thrombosis. The Botticelli DVT dose-ranging study. IRIS IRIS Home Sfoglia Macrotipologie & …
thrombosis. The Botticelli DVT dose-ranging study. IRIS IRIS Home Sfoglia Macrotipologie & …
Efficacy and safety of the oral direct factor Xa inhibitor apixaban for symptomatic deep vein thrombosis. The Botticelli DVT dose-ranging study
H Buller, D Deitchman, M Prins, A Segers… - 2008 - pubmed.ncbi.nlm.nih.gov
Background Apixaban, an oral potent reversible direct inhibitor of activated factor X, has
shown promise in the prevention of venous thromboembolism following major orthopedic …
shown promise in the prevention of venous thromboembolism following major orthopedic …